Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.

A technology of alfuzosin and udenafil, applied in the field of drugs for the treatment of overactive bladder, which can solve the unmet and growing huge demand for effective and acceptable medical treatment of overactive bladder, accompanied by side effects, etc. question

Inactive Publication Date: 2011-05-04
PELVIPHARM
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Existing therapies for overactive bladder are associated with side effects, including constipation, visual accommodation disturbances, dry eyes and dry mouth, which are difficult for some users to tolerate
Therefore, despite the availability of existing treatments, there remains a large unmet and growing need for effective and acceptable medical treatments for overactive bladder

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.
  • Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.
  • Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0082] The following examples are provided to illustrate the invention but are not intended to limit its scope.

[0083] Materials and methods

[0084] human bladder strip

[0085] The experiments, collection and use of any tissue or other samples were carried out in accordance with the research plan, all relevant laws, regulations and industry rules (including having obtained written informed consent from patients).

[0086] Bladders were obtained from donors who underwent cystectomy for invasive bladder cancer and had no known bladder dysfunction according to their medical charts. In accordance with French legislation, human tissue samples were obtained with the informed consent of the patients and after serological testing for hepatitis and HIV.

[0087] Immediately after surgery, bladder samples were transferred from the operating room to the pathologist's laboratory, who selected a piece of normal bladder dome (ie, no macroscopic tumor tissue) for experimental purposes....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.

Description

technical field [0001] The present invention relates to the use of specific combination of udenafil and alfuzosin or oxybutynin to prepare medicine for treating overactive bladder. Background technique [0002] Overactive bladder is a medical condition defined as urinary urgency (with or without urge incontinence) in the absence of other pathological or metabolic conditions that could explain the symptoms, usually with urinary frequency and nocturia . Urinary urgency is defined as a sudden and compulsive feeling to urinate that is difficult to postpone. Nocturia is defined as waking up one or more times per night to urinate. Incontinence is not a necessary condition for diagnosis, since almost half of people with overactive bladder do not have incontinence. The quality of life of patients is substantially affected by this condition, as social, psychological, occupational, family, physical and sexual functions are affected. [0003] Overactive bladder can also be caused b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/519A61K31/517A61P13/10
CPCA61K31/216A61K31/517A61K31/519A61P13/00A61P13/02A61P13/08A61P13/10A61P43/00A61K2300/00
Inventor 弗朗索瓦·朱利亚诺戴尔芬·贝尔-鲁赛尔
Owner PELVIPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com